Published January 1, 2011 | Version v1
Journal article

Combined Modality Therapy Including Intraoperative Electron Irradiation for Locally Recurrent Colorectal Cancer

  • 1. Department of Radiation Oncology, Mayo Clinic, Rochester, MN (United States)
  • 2. Division of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN (United States)
  • 3. Division of Medical Oncology, Mayo Clinic, Rochester, MN (United States)
  • 4. Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ (United States)

Description

Purpose: To evaluate survival, relapse patterns, and prognostic factors in patients with colorectal cancer relapse treated with curative-intent therapy, including intraoperative electron radiation therapy (IOERT). Methods and Materials: From April 1981 through January 2008, 607 patients with recurrent colorectal cancer received IOERT as a component of treatment. IOERT was preceded or followed by external radiation (median dose, 45.5 Gy) in 583 patients (96%). Resection was classified as R0 in 227 (37%), R1 in 224 (37%), and R2 in 156 (26%). The median IOERT dose was 15 Gy (range, 7.5-30 Gy). Results: Median overall survival was 36 months. Five- and 10-year survival rates were 30% and 16%, respectively. Survival estimates at 5 years were 46%, 27%, and 16% for R0, R1, and R2 resection, respectively. Multivariate analysis revealed that R0 resection, no prior chemotherapy, and more recent treatment (in the second half of the series) were associated with improved survival. The 3-year cumulative incidence of central, local, and distant relapse was 12%, 23%, and 49%, respectively. Central and local relapse were more common in previously irradiated patients and in those with subtotal resection. Toxicity Grade 3 or higher partially attributable to IOERT was observed in 66 patients (11%). Neuropathy was observed in 94 patients (15%) and was more common with IOERT doses exceeding 12.5 Gy. Conclusions: Long-term survival and disease control was achievable in patients with locally recurrent colorectal cancer. Continued evaluation of curative-intent, combined-modality therapy that includes IOERT is warranted in this high-risk population.

Availability note (English)

Available from http://dx.doi.org/10.1016/j.ijrobp.2009.10.046

Additional details

Identifiers

DOI
10.1016/j.ijrobp.2009.10.046;
PII
S0360-3016(09)03516-0;

Publishing Information

Journal Title
International Journal of Radiation Oncology, Biology and Physics
Journal Volume
79
Journal Issue
1
Journal Page Range
p. 143-150
ISSN
0360-3016
CODEN
IOBPD3

INIS

Country of Publication
United States
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
42083225
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
ELECTRONS; NEOPLASMS; RADIOTHERAPY; RECTUM; SURVIVAL CURVES; TOXICITY
Descriptors DEC
BODY; DIGESTIVE SYSTEM; DISEASES; ELEMENTARY PARTICLES; FERMIONS; GASTROINTESTINAL TRACT; INTESTINES; LARGE INTESTINE; LEPTONS; MEDICINE; NUCLEAR MEDICINE; ORGANS; RADIOLOGY; THERAPY

Optional Information

Copyright
Copyright (c) 2011 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.